BRCA1 and neoplasm: Therefore, if NGS-based assays are to be used on tumour tissue to determine eligibility for PARP inhibitors, it may be appropriate to consider screening for biallelic LOF (i.e. homozygosity) in RAD51C and RAD51D as well as BRCA1 and BRCA2.